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Organ shortage is one of the most serious prob-
lems for patients with end-stage renal disease
(ESRD) waiting for renal transplantation. In
2004, there were 42,550 chronic dialyzed ESRD
patients in Taiwan, but only 161 were lucky
enough to receive renal transplantation from de-
ceased donors.1,2 Another 46 patients underwent
living-related renal transplantation.2 Renal trans-
plants either from genetically related or from
unrelated live donors have yielded excellent sur-
vival rates. Evidence indicates that there is little
rlong-term medical risk to a healthy donor afte
unilateral nephrectomy.3 fThe annual number o
live kidney donors in the United States has sur-
passed that of deceased donors since 2001.4
Blood type compatibility between donor and
recipient has been a determining factor in conduct-
ing organ transplantation. ABO-incompatible renal
transplantation has long been considered to run a
high risk of rejection and graft loss. With advances
cin immunosuppressive agents and therapeuti
plasmapheresis, excellent long-term outcome has
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The serious shortage of cadaveric organs has prompted the development of ABO-incompatible live donor
renal transplantation. We report our experience of the initial two live donor ABO incompatible renal
transplants at our hospital. The first patient was a 55-year-old type A female who received a kidney from
her AB type husband. The second patient was a 27-year-old type O male who received renal transplanta-
tion from his type A father. Preconditioning immunosuppressive therapy in the two patients with
tacrolimus, mycophenolate mofetil and methylprednisolone was started 7 days before transplantation.
During the period of preconditioning, double filtration plasmapheresis (DFPP) was employed to remove
anti-A and -B antibodies. Laparoscopic splenectomy and renal transplantation were performed after the
anti-donor ABO antibodies were reduced to a titer of 1:4. Rituximab, a humanized monoclonal anti-
CD20 antibody, was administered to the second patient due to a rebound in the anti-A antibody titer dur-
ing the preconditioning period. Under a tacrolimus-based immunosuppressive regimen, both patients
recovered very well without any evidence of rejection. Serum creatinine levels were 1.0 and 1.4 mg/dL at 6
and 3 months after transplantation, respectively. These cases illustrate that with new immunosuppressive
agents, DFPP and splenectomy, ABO-incompatible renal transplantation can be successfully conducted in
end-stage renal disease patients whose only available live donors are blood group incompatible. [J Formos
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CASE REPORT
been achieved in ABO-incompatible live donor
renal transplantation in Japan.5,6 We accordingly
attempted to establish this transplant modality for
ESRD patients with potential ABO-incompatible
live donors in Taiwan. Here, we report our initial
experience with two patients who received ABO-
incompatible live donor renal transplantation.
Case Reports
Case 1
A 55-year-old woman with blood type A was ad-
mitted because of intermittent lower leg edema
for 20 years. Despite records indicating elevated
blood pressure and fasting blood sugar several
years ago, no regular medical treatment had
been given. Physical examination showed pale
conjunctivae and mild pitting edema in the
lower extremities. Laboratory data showed a
leukocyte count of 7450/mm3, hemoglobin of
8.9 g/dL and platelet count of 231,000/mm3.
Biochemistry studies showed serum creatinine of
8.4 mg/dL and blood urea nitrogen of 97.2 mg/dL.
Chronic renal failure was diagnosed. Her family
was willing to donate a kidney to her, but all
family members were of AB blood type. Her hus-
band, a 57-year-old man with type AB blood
type, decided to donate his kidney for ABO-
incompatible live donor renal transplantation.
Typing of human lymphocyte antigens (HLA)
showed that the donor was 1, 0, 1 (HLA-A, B, DR)
mismatched with the recipient. Details of pre-
transplant immunologic evaluations, including
blood type, HLA, recipient panel reactive anti-
tbody and donor-specific complement-dependen
cytotoxicity, are shown in the Table.
After admission, the patient received four ses-
sions of double filtration plasmapheresis
(DFPP) to reduce the anti-B antibody titer from
1:16 to 1:2. Anti-A and -B antibody titer was
 determined using the saline method. Twofold
serial dilutions of sera were made in saline and
tested for agglutinating activity toward A or B red
blood cells respectively and were subjected to
centrifugation with a blood bank serocentrifuge.
Titers were read macroscopically. DFPP was per-
formed using KM-8800 in a Kuraray plasma-
pheresis system (Kuraray, Okayama, Japan)
incorporating a Plasmacure PS-06 as the plasma
separator and an Evaflux 5A as the plasma frac-
ttionator (Kuraray). The exchange volume was se
at 50 mL/kg with normal saline 300–500 mL as
the replacement fluid.
tIn addition to plasmapheresis, the patien
received a 7-day tacrolimus-based immunosup-
pressive therapy including tacrolimus (Prograf,
Fujisawa, London, UK), mycophenolate mofetil
(MMF; Cellcept, Roche, Humacao, Puerto Rico)
and methylprednisolone before transplantation.
The initial dose of tacrolimus was 0.2 mg/kg/day,
and the trough blood levels of tacrolimus were
maintained around 10 ng/mL by dose adjust-
ment. The daily dose of MMF was 2 g/day and
rthat of methylprednisolone was 80 mg/day. Live
function tests, complete blood counts, blood
sugar and coagulation profiles were checked
fevery other day to facilitate early identification o
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Table. Results of pretransplant immunologic examinations in cases 1 and  2, including blood type, human
lymphocyte antigen, recipient panel reactive antibody and donor-specific complement-dependent
cytotoxicity
Case
Blood type/HLA PRA (%)
CDC
Donor Recipient Class I Class II
1 AB A11/B60, Bw6/Cw7/ A A26/B60, Bw6/Cw7/ 0 0 Negative
DR9, DR11, DR52, DR53 DR11, DR15, DR51, DR52
2 A A2/B75, B46, Bw6/Cw1, Cw8/ O A2/B46/Cw1/DR9, DR53 0 0 Negative
DR9, DR12, DR52, DR53
HLA = human lymphocyte antigen; PRA = panel reactive antibody; CDC = complement-dependent cytotoxicity.
side effects of DFPP and the immunosuppressive
drugs. Intravenous immunoglobulin was not
given but fresh frozen plasma was administered
for correction of coagulopathy.
Our first ABO-incompatible live donor renal
transplantation was conducted on November 22,
2004. Laparoscopic nephrectomy was performed
to retrieve the left kidney of the donor, and the re-
cipient received laparoscopic splenectomy.7,8 After
splenectomy, the spleen was left behind in the
peritoneal cavity until accomplishment of vascu-
lar and urinary reconstruction of the graft kidney.
The spleen was then pulled out of the abdominal
cavity through the incision for the renal implanta-
tion. During the transplant operation, bolus intra-
venous methylprednisolone (10 mg/kg) was given
before vascular reperfusion. The dose of methyl-
prednisolone was then tapered to 20 mg/day by
day 8 and changed to oral prednisolone thereafter.
Continuous intravenous infusion of tacrolimus
was administered until the patient could tolerate
oral tacrolimus. The doses of tacrolimus were ad-
justed to achieve a target blood level of 10 ng/mL
for the first 3 months, and those of prednisolone
were tapered to 0.1 mg/kg/day in month 3. MMF
was given at a dose of 2 g/day initially, with the
dosage adjusted to keep the white blood cell
counts in the range of 4000–6000/mm3. The post-
operative course was uneventful and the renal
function of the graft was good. Neither signs of re-
jection nor anti-B antibody rebound was detected.
The patient was discharged 3 weeks after the 
operation. The serum creatinine level was 1.0 mg/
dL with an anti-B antibody titer of 1:2 6 months
after the transplant. Details of the serum creati-
nine levels and anti-B antibody titers of case 1 are
summarized in Figure A.
Case 2
A 27-year-old man with blood type O was admit-
ted for live donor renal transplantation. His father,
a 45-year-old man of blood type A, expressed his
desire to donate a kidney to him. The patient had
developed gouty arthritis without regular medical
treatment several years ago. His renal function had
progressively deteriorated, and he had received
chronic peritoneal dialysis for 3 years. Physically,
he was anemic with pale conjunctivae. Hemo-
globin level was 8.5 g/dL and platelet count was
216,000/mm3 L. Serum creatinine was 16.3 mg/d
Aand blood urea nitrogen was 87.3 mg/dL. Anti-
and -B antibody titers were 1:64 and 1:16, respec-
ctively. Results of the pretransplant immunologi
evaluations are shown in the Table.
After admission, the patient received the same
preconditioning immunosuppressive regimen as
in case 1. However, six sessions of DFPP were
required to reduce the anti-A antibody titer to
1:4. The anti-A antibody titer rebounded once
during the course of DFPP (Figure B). Rituximab
(MabThera, Roche, Hertfordshire, UK), a mono-
clonal anti-CD20 antibody, was additionally given
at a dose of 375 mg/m2 before graft reperfusion
to deplete the patient’s B-lymphocytes. The
ABO-incompatible renal transplantation
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iF gure. Pre- and post-transplant serum creatinine levels (sCr) and anti-blood group antibody titers in: (A) Case 1; (B) Case 2.
(∇ = double filtration plasmapheresis; ↓ = splenectomy and renal transplantation; ⇓ = rituximab therapy.)
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transplant operation was conducted and post-
transplant immunosuppressive therapy was as
described in case 1. Although the graft renal func-
tion was good, the patient suffered from severe
epigastralgia and vomiting after the operation.
MMF was discontinued and changed to sirolimus
(Rapaume, Wyeth-Ayerst, PA, USA) 10 days post-
transplantation. The serum creatinine level was
1.4 mg/dL and the anti-A antibody titer was 1:4 3
months after transplantation. The pre- and post-
transplant serum creatinine levels and anti-A anti-
body titers of case 2 are summarized in Figure B.
Discussion
ABO-incompatible renal transplantation is an al-
ternative therapeutic modality for ESRD patients
whose only live donors have incompatible blood
groups. Takahashi et al9 reported that the out-
come of ABO-incompatible renal transplantation
was similar to ABO-compatible transplantation.
The excellent long-term outcome in Japan fully
justified ABO-incompatible live donor renal trans-
plantation in countries extremely short of cadav-
eric kidneys with strict requirement for living
donation.6 The success in overcoming ABO in-
compatibility in these two cases may serve as a
model for increasing the pool of live donors and
the number of renal transplantations in Taiwan.
Immunosuppressive therapy plays a central
role in ABO-incompatible renal transplantation.
Tacrolimus has been demonstrated to have a 
potent immunosuppressive effect resulting in
good renal function in randomized studies world-
wide.10,11 MMF has been shown to suppress the
production of anti-blood type antibodies in ABO-
incompatible transplantation.12 These properties
have led to the use of tacrolimus and MMF ther-
apy in nearly all the reports on ABO-incompatible
renal transplantation. The success of ABO-
incompatible renal transplantation also depends
on effective removal of anti-A and -B antibodies
and splenectomy.13,14 While DFPP is associ-
ated with hypoalbuminemia and coagulopathy,
antigen-specific immunoadsorption of anti-A or -B
antibody is a preferable alternative to DFPP in
ABO-incompatible transplantation.15 However,
we chose to employ DFPP because the im-
munoadsorption columns for anti-A and -B anti-
bodies are not available in Taiwan. Besides,
DFPP can remove not only anti-A and -B but also
anti-HLA antibodies in patients who are positive
for panel reactive antibodies. Successful applica-
tion of DFPP in transplant recipients could be an
initial step toward transplantation with donor-
specific preformed antibodies.
The requirement for splenectomy in ABO-
incompatible transplantation is debatable, espe-
cially with the advent of rituximab. Rituximab is
ya humanized monoclonal anti-CD20 antibod
fthat was primarily approved for therapy o
CD20-positive B-cell lymphoma. Rituximab has
been successfully adopted as a B-cell ablative
ragent in immunosuppressive preconditioning fo
ABO-incompatible renal transplantation with-
out splenectomy.16,17 In case 2, we encountered
difficulty in reducing the anti-A antibody titer to
the target level, and successful reduction of anti-
A titer was actually achieved by intensive DFPP.
The risk of humoral rejection might have been
very high if further immune intervention had
not been instituted.18 We therefore classified case
2 as resistant to DFPP and gave rituximab in
order to prevent antibody rebound and humoral
rejection.19 Large-scale randomized trials are
needed to investigate the effect of rituximab on
the outcome of allograft transplantation.
In summary, this report describes two suc-
rcessful cases of ABO-incompatible live dono
renal transplantation. With the use of new im-
munosuppressive agents, DFPP and splenec-
tomy, ABO-incompatible renal transplantation is
fan established alternative for the treatment o
ESRD patients whose only live donors are blood
group incompatible.
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